脂必妥与辛伐他汀调节血脂代谢的成本-效果分析

Cost-effectiveness analysis of zhibituo and simvastatin in treatment of hyperlipemia

目的对辛伐他汀片与脂必妥胶囊调节血脂代谢成本-效益分析。方法原发性血脂代谢紊乱患者68例被随机分为两组：A组服用辛伐他汀，B组服用脂必妥，采用药物经济学成本．效果分析法，统计两组治疗方法经过8周治疗后的费用和临床疗效，计算出成本-效果比和增量成本．效果比。结果两组治疗费用分别为462．56元和257．60元，总有效率分别为74．28％和73．93％，成本-效果比分别为6．23和3．48，A组对B组的增量成本为585．6，两组间疗效和不良反应差异无统计学意义（P〉0．05）。结论脂必妥胶囊调节血脂代谢能减轻患者负担，疗效与辛伐他汀片相同。

Objective To explore the cost-effectiveness analysis of zhibituo and simvastadn in treatment of hyperlipemia. Methods 68 cases with hyperlipemia were divided into two groups randomly：group A were treated with imvastatin （ n = 33）, group B were treated with zhibituo（ n = 35 ）, The data was evaluated with cost-effectiveness analysis. Results The cost of the two groups was 462.56 yuan and 257.60 yuan respectively. The effective rate was 74.28 % and 73.93 % respectively. The cost-effectiveness ratio was 6.23 and 3.48 respectively. The increased cost-effectiveness ratio of group A vs group B was 585.6. No significant differences were found in both effective rate and ADRS between two groups（P 〉 0.05 ）. Conclusion Zhibltuo was an effective and safe drug in treating hyperlipidemia as well as simvastatin. But zhibituo was better than simvastatin based on the cost-effectiveness analysis.